Semaglutide is a GLP-1 receptor agonist (single target)
Explore the market dynamics behind GLP-1 growth in the latest reports at #CDMO #BiopharmaManufacturing #LifeSciences #NiceInsight GLP-1 Market Shift: Semaglutide, Tirzepatide Dominate The GLP-1 market has turned into a heavyweight duel
Price is right, too
GLP-1 Agonists Market Size, Share & Trends Analysis Report By Product (Branded GLP-1 Agonists, Dual / Triple, Biosimilars & Generic GLP-1 Agonists Agonists), By Indication (Type 2 Diabetes Mellitus, Obesity / Overweight Management, Cardiovascular & Metabolic Related Indications, Other Emerging Indications (e.g., NASH, Alzheimers-related)), By Route of Administration, By Distribution Channel, By Region and By Segments Forecasts, 2025-2034 GLP-1 Agonists Market Size is valued at USD 43.1 Bn in 2024 and is predicted to reach USD 260.1 Bn by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034
Will I need to take a pill or give myself an injection for each dose of this medication
To view a copy of this licence, visit About this article Cite this article Rico-Fontalvo, J., Daza-Arnedo, R., Elbert, A